DOCSLIB.ORG

Cystic Fibrosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cystic Fibrosis cf_new3.qxd 2/21/96 3:14 PM Page 1 FACTS ABOUT Cystic Fibrosis What Is Cystic Fibrosis What Are the Signs and Symptoms Cystic fibrosis (CF) is a chronic, progressive, of CF? and frequently fatal genetic (inherited) dis­ CF does not follow the same pattern in all ease of the body’s mucus glands. CF pri­ patients but affects different people in dif­ marily affects the respiratory and digestive ferent ways and to varying degrees. systems in children and young adults. The However, the basic problem is the same— sweat glands and the reproductive system an abnormality in the glands, which pro­ are also usually involved. On the average, duce or secrete sweat and mucus. Sweat individuals with CF have a lifespan of cools the body; mucus lubricates the respi­ approximately 30 years. ratory, digestive, and reproductive systems, and prevents tissues from drying out, pro­ CF-like disease has been known for over tecting them from infection. two centuries. The name, cystic fibrosis of the pancreas, was first applied to the disease People with CF lose excessive amounts of in 1938. salt when they sweat. This can upset the balance of minerals in the blood, which may How Common Is CF? cause abnormal heart rhythms. Going into shock is also a risk. According to the data collected by the Cystic Fibrosis Foundation, there are about Mucus in CF patients is very thick and 30,000 Americans, 3,000 Canadians, and accumulates in the intestines and lungs. 20,000 Europeans with CF. The disease The result is malnutrition, poor growth, occurs mostly in whites whose ancestors frequent respiratory infections, breathing came from northern Europe, although it difficulties, and eventually permanent lung affects all races and ethnic groups. damage. Lung disease is the usual cause of Accordingly, it is less common in African death in most patients. Americans, Native Americans, and Asian CF can cause various other medical prob­ Americans. Approximately 2,500 babies are lems. These include sinusitis (inflammation born with CF each year in the United of the nasal sinuses, which are cavities in States. Also, about 1 in every 20 the skull behind, above, and on both sides Americans is an unaffected carrier of an of the nose), nasal polyps (fleshy growths abnormal “CF gene.” These 12 million inside the nose), clubbing (rounding and people are usually unaware that they are enlargement of fingers and toes), pneu­ carriers. mothorax (rupture of lung tissue and trap- NATIONAL INSTITUTES OF HEALTH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE cf_new3.qxd 2/21/96 3:15 PM Page 2 ping of air between the lung and the chest wall), hemoptysis (coughing of CYSTIC FIBROSIS GENE blood), cor pulmonale (enlargement of the right side of the heart), AUTOSOMAL RECESSIVE INHERITANCE abdominal pain and discomfort, gassiness (too much gas in the intes­ Carrier Father Carrier Mother tine), and rectal prolapse (protrusion of the rectum through the anus). Liver disease, diabetes, inflammation of the pancreas, and gallstones also occur in some people with CF. When Should You Suspect That a Child May Have CF? CF symptoms vary from child to child. A baby born with the CF genes usually has symptoms during Gg Gg its first year. Sometimes, however, signs of the disease may not show up until adolescence or even later. Infants or young children should be tested for CF if they have persistent GG Gg Gg gg diarrhea, bulky foul-smelling and greasy stools, frequent wheezing or pneumonia, a chronic cough with thick mucus, salty-tasting skin, or poor growth. CF should be suspect­ ed in babies born with an intestinal blockage called meconium ileus. How Is CF Diagnosed? Normal Carrier Carrier Affected The most common test for CF is called the sweat test. It measures the amount of salt (sodium chloride) in The presence of two mutant genes (g) is needed for CF to appear. Each parent the sweat. In this test, an area of the carries one defective gene (g) and one normal gene (G). The single normal skin (usually the forearm) is made to gene is sufficient for normal function of the mucus glands, and the parents are sweat by using a chemical called therefore CF-free. Each child has a 25 percent risk of inheriting two defective pilocarpine and applying a mild elec­ genes and getting CF, a 25 percent chance of inheriting two normal genes, tric current. To collect the sweat, the and a 50 percent chance of being an unaffected carrier like the parents. area is covered with a gauze pad or filter paper and wrapped in plastic. After 30 to 40 minutes, the plastic is removed, and the sweat collected in the pad or paper is analyzed. Higher than normal amounts of sodium and 2 cf_new3.qxd 2/21/96 3:15 PM Page 3 chloride suggest that the person has can cause the body to make a defec­ for the basic causes of CF, although cystic fibrosis. tive protein or no protein at all. The several drug-based approaches are result is a loss of some essential bio­ being investigated. In the mean­ The sweat test may not work well in logical function and that leads to time, the best that doctors can do is newborns because they do not pro­ disease. Children may inherit altered to ease the symptoms of CF or slow duce enough sweat. In that case, genes from one or both parents. the progress of the disease so the another type of test, such as the patient’s quality of life is improved. immunoreactive trypsinogen test Diseases such as CF that are caused This is achieved by antibiotic thera­ (IRT), may be used. In the IRT test, by inherited genes are called genetic py combined with treatments to blood drawn 2 to 3 days after birth diseases. In CF, each parent carries clear the thick mucus from the is analyzed for a specific protein one abnormal CF gene and one nor­ lungs. The therapy is tailored to the called trypsinogen. Positive IRT mal CF gene but shows no evidence needs of each patient. For patients tests must be confirmed by sweat of the disease because the normal CF whose disease is very advanced, lung and other tests. gene dominates or “recesses” the transplantation may be an option. abnormal CF gene. To have CF, a Also, a small percentage of people child must inherit two abnormal CF was once always fatal in child­ with CF have normal sweat chloride genes—one from each parent. The hood. Better treatment methods levels. They can only be diagnosed recessive CF gene can occur in both developed over the past 20 years by chemical tests for the presence of boys and girls because it is located have increased the average lifespan the mutated gene. Some of the on non-sex-linked chromosomes of CF patients to nearly 30 years. other tests that can assist in the called autosomal chromosomes. CF These treatment approaches are diagnosis of CF are chest x-rays, is therefore called an autosomal detailed more fully below: lung function tests, and sputum recessive genetic disease. (phlegm) cultures. Stool examina­ ■ Management of lung problems tions can help identify the digestive The inheritance patterns for the CF A major focus of CF treatment is the abnormalities that are typical of CF. gene are shown in the accompany­ obstructed breathing that causes ing diagram. Each child, whether frequent lung infections. Physical What Makes CF a Genetic male or female, has a 25 percent risk therapy, exercise, and medications Disease? of inheriting a defective gene from are used to reduce the mucus block­ each parent and of having CF. A Genes are the basic units of heredity. age of the lung’s airways. child born to two CF patients (an They are located on structures with­ unlikely event) would be at a 100 Chest therapy consists of bronchial, in the cell nucleus called chromo­ percent risk of developing CF. or postural, drainage, which is done somes. The function of most genes by placing the patient in a position is to instruct the cells to make par­ that allows drainage of the mucus ticular proteins, most of which have How Is CF Treated? from the lungs. At the same time, important life-sustaining roles. Since CF is a genetic disease, the the chest or back is clapped (per­ only way to prevent or cure it would Every human being has 46 chromo­ cussed) and vibrated to dislodge the be with gene therapy at an early somes, 23 inherited from each par­ mucus and help it move out of the age. Ideally, gene therapy could ent. Because each of the 23 pairs of airways. This process is repeated repair or replace the defective gene. chromosomes contains a complete over different parts of the chest and Another option for treatment would set of genes, every individual has back to loosen the mucus in differ­ be to give a person with CF the two sets (one from each parent) of ent areas of each lung. This proce­ active form of the protein product genes for each function. In some dure has to be done for children by that is scarce or missing. individuals, the basic building family members but older patients blocks of a gene (called base pairs) At present, neither gene therapy nor can learn to do it by themselves. are altered (mutated). A mutation any other kind of treatment exists Mechanical aids that help chest 3 cf_new3.qxd 2/21/96 3:15 PM Page 4 physical therapy are available com­ treat the gene abnormality that mercially. Exercise also helps to causes CF.
Load more

Recommended publications
  • Laryngopharyngeal Reflux and Chronic Cough Disclosure
    Brett MacFarlane Laryngopharyngeal reflux and chronic cough A therapeutic dilemma 1 Disclosure I have received honoraria, speaker fees, consultancy fees, travel support, am a member of advisory boards or have appeared on expert panels for: Reckitt Benkiser, Bayer, Blackmores Produce education material for AJP, Retail Pharmacy, ITK, ACP 2 Disclaimer The information contained herein has not been independently verified, confirmed, reviewed or endorsed by Reckitt Benckiser. No consideration, in any form, has been provided or promised by Reckitt Benckiser in connection with or arising out of this presentation, and all findings are based on my own independent research, experience and expert opinion. The information contained herein is for guidance only and pharmacists are encouraged to conduct their own enquiries. No representation warranty, express or implied, is made as to the accuracy, reliability or correctness of the information contained herein and all liability is disclaimed arising out of or in connection with any reliance on this presentation or the information contained herein. 3 Learning objectives After completing this activity, pharmacists should be able to: 1. Describe laryngopharyngeal reflux (LPR) and how it relates to chronic cough 2. Describe the challenges of diagnosing LPR 3. Outline the management of LPR 4 What does reflux mean to you? Heartburn Acid Burning Rising into the oesophagus 5 What does chronic cough mean to you? Respiratory Asthma COPD Infection Smoking Cancer 6 Reflux is more than just acid Refluxate also contains: Pepsin (stomach) Trypsin (duodenum) Bile salts 7 Causes of chronic cough 29% asthma 33% reflux Li X, et al. Gastroesophageal Reflux Disease and Chronic Cough: A Possible Mechanism Elucidated by Ambulatory pH‐impedance‐pressure Monitoring.
    [Show full text]
  • GERD and Coughing, What PIDD Patients Need to Know
    By Dharshini Mahadevan, MPH While the cause of GERD is not or many with primary immune deficiency disease (PIDD), a chronic cough is nothing new. According to Annette known, the symptoms and what F Zampelli, MSN, CRNP, a medical science liaison for CSL they trigger in PIDD patients can Behring, as well as a former clinician in the Pediatric, Allergy and Immunology Department at Penn State Children’s Hospital, a often be controlled with lifestyle potential culprit of their cough—gastroesophageal reflux disease and dietary changes. (GERD)—is often overlooked. “A lot of people think they’re just having sinus drainage,” said Zampelli, who also suffers from GERD, as well as common variable immune deficiency (CVID). “Or, they may blame coughing on asthma.” Because Zampelli deals with GERD herself, she can often immediately recognize it in others. She recalls one incident during which she realized an individual was refluxing within minutes of meeting her. “A lot of people have chronic hoarseness and intermittent coughing because GERD can cause a laryngeal spasm,” explains Zampelli. “It also causes inflammation of the vocal While the exact cause of cords, which causes them to spasm and leads to irritation to the surrounding tissues.” GERD remains unknown, To determine whether GERD is a factor in one’s cough, Zampelli recommends that patients pay attention to whether many believe hiatal hernias they wake up with morning hoarseness, if they seem to cough more after they lie down or if certain foods make their are a main cause. symptoms worse. In addition, Zampelli suggests that patients track symptoms by using “a food diary to see if there’s any correlation with certain things.
    [Show full text]
  • Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1
    ISSN: 2572-4193 Gelpi et al. J Otolaryngol Rhinol 2018, 4:036 DOI: 10.23937/2572-4193.1510036 Volume 4 | Issue 1 Journal of Open Access Otolaryngology and Rhinology CASE REPORT Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1 1 Check for University Hospitals Cleveland Medical Center, USA updates 2Case Western Reserve University School of Medicine, USA *Corresponding author: Mark Gelpi, MD, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA, Tel: (216)-844-8433, Fax: (216)-201-4479, E-mail: [email protected] paranasal sinuses [1,4]. Nasal symptoms in CF patients Abstract occur early, manifesting between 5-14 years of age, and Cystic fibrosis (CF) is a multisystem disease that can have represent a life-long problem in this population [5]. Pa- significant sinonasal manifestations. Viscous secretions are one of several factors in CF that result in chronic sinona- tients with CF can develop thick nasal secretions con- sal pathology, such as sinusitis, polyposis, congestion, and tributing to chronic rhinosinusitis (CRS), nasal conges- obstructive crusting. Persistent discomfort and nasal man- tion, nasal polyposis, headaches, and hyposmia [6-8]. ifestations of this disease significantly affect quality of life. Sinonasal symptoms of CF are managed medically with Digital manipulation and removal of crusting by the patient in an attempt to alleviate the discomfort can have unfore- topical agents and antibiotics, however surgery can be seen damaging consequences. We present one such case warranted due to the chronic and refractory nature of and investigate other cases of septal damage secondary to the symptoms, with 20-25% of CF patients undergoing digital trauma, as well as discuss the importance of sinona- sinus surgery in their lifetime [8].
    [Show full text]
  • Cryptogenic Organizing Pneumonia—Results of Treatment with Clarithromycin Versus Corticosteroids—Observational Study
    RESEARCH ARTICLE Cryptogenic organizing pneumoniaÐResults of treatment with clarithromycin versus corticosteroidsÐObservational study Elżbieta Radzikowska1*, Elżbieta Wiatr1☯, Renata Langfort2³, Iwona Bestry3³, Agnieszka Skoczylas4, Ewa Szczepulska-Wo jcik2³, Dariusz Gawryluk1☯, Piotr Rudziński5³, Joanna Chorostowska-Wynimko6³, Kazimierz Roszkowski-Śliż1³ 1 III Department of Lung Disease National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 2 Pathology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 3 Radiology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, a1111111111 Poland, 4 Geriatrics Department National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, a1111111111 Poland, 5 Thoracic Surgery Department National Tuberculosis and Lung Diseases Research Institute, a1111111111 Warsaw, Poland, 6 Laboratory of Molecular Diagnostics and Immunology National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland a1111111111 a1111111111 ☯ These authors contributed equally to this work. ³ These authors also contributed equally to this work. * [email protected] OPEN ACCESS Abstract Citation: Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-WoÂjcik E, et al. (2017) Cryptogenic organizing pneumoniaÐ Background Results of treatment with clarithromycin versus Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown ori- corticosteroidsÐObservational study. PLoS ONE 12(9): e0184739.
    [Show full text]
  • Does Cystic Fibrosis Constitute an Advantage in COVID-19 Infection? Valentino Bezzerri, Francesca Lucca, Sonia Volpi and Marco Cipolli*
    Bezzerri et al. Italian Journal of Pediatrics (2020) 46:143 https://doi.org/10.1186/s13052-020-00909-1 LETTER TO THE EDITOR Open Access Does cystic fibrosis constitute an advantage in COVID-19 infection? Valentino Bezzerri, Francesca Lucca, Sonia Volpi and Marco Cipolli* Abstract The Veneto region is one of the most affected Italian regions by COVID-19. Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), may constitute a risk factor in COVID-19. Moreover, respiratory viruses were generally associated with severe pulmonary impairment in cystic fibrosis (CF). We would have therefore expected numerous cases of severe COVID-19 among the CF population. Surprisingly, we found that CF patients were significantly protected against infection by SARS-CoV-2. We discussed this aspect formulating some reasonable theories. Keywords: Cystic fibrosis, SARS-CoV-2, Covid-19, Azythromycin, DNase Introduction status, one would surmise that CF patients would be at The comorbidities of obesity, hypertension, diabetes, an increased risk of developing severe COVID-19 illness. heart failure, and chronic lung disease have been associ- ated with poor outcome in coronavirus disease 2019 Methods (COVID-19) [1]. Once Severe Acute Respiratory Syn- We conducted a retrospective study of 532 CF patients – drome (SARS) Coronavirus (CoV)-2 has infected host followed at the Cystic Fibrosis Center of Verona, Italy. cells, excessive inflammatory and thrombotic processes SARS-CoV-2 positivity was tested by collecting com- take place. A cytokine storm release with markedly ele- bined nose-throat swabs and subsequent Real-Time PCR vated IL-6 levels are associated with increased lethality using the Nimbus MuDT tm (Seegene, Seoul, South [2].
    [Show full text]
  • Bronchodilator Responsiveness in Children with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
    AGORA | RESEARCH LETTER Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Mordechai Pollak 1, Michelle Shaw2, David Wilson1, Hartmut Grasemann1,2 and Felix Ratjen1,2 Affiliations: 1Division of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada. 2Translational Medicine, Sickkids Research Institute, Toronto, ON, Canada. Correspondence: Mordechai Pollak, Hospital for Sick Children, SickKids Learning Institute, Respiratory Medicine, 555 University Ave, Toronto, ON M5G 1X8, Canada. E-mail: [email protected] @ERSpublications CF patients with a new diagnosis of ABPA had a similar BD response, compared to CF patients with acute lung function deterioration from other causes. BD response testing did not help differentiating ABPA from other causes of lung function deterioration. https://bit.ly/39Oegnh Cite this article as: Pollak M, Shaw M, Wilson D, et al. Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. Eur Respir J 2020; 56: 2000175 [https://doi.org/ 10.1183/13993003.00175-2020]. This single-page version can be shared freely online. To the Editor: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease that occurs in approximately 9% of children with cystic fibrosis (CF) [1]. While ABPA is commonly associated with worsening lung function, differentiating ABPA from other causes of pulmonary function decline often poses a clinical challenge. This is reflected by major differences among the various diagnostic criteria for ABPA that have been suggested to date [2–5]. A positive bronchodilator response (BDR) is characteristic for asthma which is a common co-morbidity in CF patients, but whether this is helpful in differentiating ABPA from other causes of deterioration in lung function is currently unclear.
    [Show full text]
  • Infection Control Recommendations for Patients with Cystic Fibrosis
    S6 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY May 2003 INFECTION CONTROL RECOMMENDATIONS FOR PATIENTS WITH CYSTIC FIBROSIS: MICROBIOLOGY, IMPORTANT PATHOGENS, AND INFECTION CONTROL PRACTICES TO PREVENT PATIENT-TO-PATIENT TRANSMISSION Lisa Saiman, MD, MPH; Jane Siegel, MD; and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants EXECUTIVE SUMMARY (d) The previously published HICPAC/CDC guidelines for Infection Control Recommendations for Patients With prevention of healthcare-associated infections have not Cystic Fibrosis: Microbiology, Important Pathogens, and included background information and recommenda- Infection Control Practices to Prevent Patient-to-Patient tions for the specific circumstances of patients with CF. Transmission updates, expands, and replaces the con- Thus, specific guidelines for CF patients are needed. sensus statement, Microbiology and Infectious Disease in (e) The link between acquisition of pathogens and morbidity Cystic Fibrosis published in 1994.1 This consensus docu- and mortality is well established. Prevention of acquisi- ment presents background data and evidence-based rec- tion of specific pathogens may further improve the mean ommendations for practices that are intended to decrease survival of CF patients, which has increased to 33.4 years the risk of transmission of respiratory pathogens among in 2001.3-9 CF patients from contaminated respiratory therapy equip- A multidisciplinary committee consisting of health- ment or the contaminated environment and thereby reduce care professionals from the United States, Canada, and the burden of respiratory illness. Included are recommen- Europe with experience in CF care and healthcare epi- dations applicable in the acute care hospital, ambulatory, demiology/infection control reviewed the relevant litera- home care, and selected non-healthcare settings.
    [Show full text]
  • Cough Hypersensitivity in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
    Sleep and Breathing (2019) 23:33–39 https://doi.org/10.1007/s11325-018-1641-7 SLEEP BREATHING PHYSIOLOGY AND DISORDERS • ORIGINAL ARTICLE Cough hypersensitivity in patients with obstructive sleep apnea hypopnea syndrome Cuiqin Shi1 & Siwei Liang1 & Xianghuai Xu1 & Qiang Chen1 & Lan Wang1 & Li Yu1 & Hanjing Lv 1 & Zhongmin Qiu1 Received: 24 May 2017 /Revised: 5 February 2018 /Accepted: 6 February 2018 /Published online: 16 February 2018 # Springer International Publishing AG, part of Springer Nature 2018 Abstract Purpose The purpose of this study was to investigate cough hypersensitivity and its potential mechanisms in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Methods Fifteen OSAHS patients, 12 simple snoring patients, and 15 healthy volunteers received cough sensitivity test and induced sputum cytology. Cough thresholds C2 and C5 (the minimum of capsaicin inducing ≥ 2and≥ 5 coughs, respectively), total cell count, cell differentials and the levels of bradykinin, histamine, prostaglandin E2, substance P, calcitonin gene-related peptide, pepsin, and interleukin-2 in the induced sputum detected by enzyme-linked immunosorbent assay were compared. The linear correlation between lgC2 and lgC5 and apnea hypopnea index, cell differentials, and inflammatory mediators in the induced sputum was calculated in OSAHS patients. Results OSAHS patients presented with a significant lower C2 and C5 (P < 0.01), increased lymphocyte but decreased macro- phage and neutrophil proportions in the induced sputum (P < 0.01), and higher contents of substance P, calcitonin gene-related peptide and interleukin-2 (P < 0.01) but similar levels of bradykinin, pepsin, prostaglandin E2, and histamine (P > 0.05) in the supernatant of induced sputum, when compared with simple snoring patients and healthy volunteers.
    [Show full text]
  • The Cystic Fibrosis Foundation Leading the Way
    The Cystic Fibrosis Foundation Leading the Way Cystic fibrosis is a rare, genetic disease that progressively limits the ability to breathe. To combat this condition, the Cystic Fibrosis Foundation was founded in 1955 by parents desperate to save their children’s lives. Their impassioned determination to prolong life has resulted in tremendous strides over the past 60 years in accelerating research and drug development. About cystic fibrosis Median predicted age is into the Americans are symptomless carriers Americans have CF. of the defective CF gene. Living with CF is a struggle The defective CF Some with CF gene causes a thick say it feels buildup of like they are mucus in breathing the lungs through and the a straw. hours a day are spent pancreas. doing treatments. (That’s 1 month a year.) A long, costly road to a cure promising therapies are was spent by the CF Foundation on cures exist currently in development. its mission and advancing new for cystic fibrosis. therapies over the past 25 years. We will not rest until we have a cure for those living with cystic fibrosis. The CF Foundation is a proven leader in the field of rare disease research and is recognized globally for its unprecedented advancements. The Foundation will continue to invest heavily in science supporting its mission so that we can add tomorrows to the lives of those with this disease – and help improve quality of life today. As of September 2018 Jordan, age 22 While people with CF are living longer than in the past, we still lose precious young lives every day.
    [Show full text]
  • Article First Wave of COVID-19 in French Patients with Cystic Fibrosis
    Supplementary material First Wave of COVID-19 in French Patients with Cystic Fibrosis Harriet Corvol 1,2,*, Sandra de Miranda 3, Lydie Lemonnier 4, Astrid Kemgang 2, Martine Reynaud Gaubert 5,6, Raphael Chiron 7, Marie-Laure Dalphin 8, Isabelle Durieu 9, Jean-Christophe Dubus 10, Véronique Houdouin 11, Anne Prevotat 12, Sophie Ramel 13, Marine Revillion 14, Laurence Weiss 15, Loic Guillot 2, Pierre-Yves Boelle 16 and Pierre-Régis Burgel 17,18 on behalf the French Cystic Fibrosis Reference Network study group Supplementay material Expected Number and Age Distribution of COVID-19 in French Patients with Cystic Fibrosis We obtained the cumulated number of hospitalized COVID-19 cases in the French general population up to 30 June 2020. These data are open source, available from data.gouv.fr (https://www.data.gouv.fr/fr/datasets/r/41b9bd2a-b5b6-4271-8878-e45a8902ef00). Then, we obtained the probability of hospitalization upon SARS-Cov-2 infection by age from Table S1 in Salje et al. [21]. The numbers of people in each age class in France were obtained from census data (https://www.insee.fr/fr/statistiques/1892086?sommaire=1912926). From these data, we computed the extrapolated percentage of infections by age class up to 30 June 2020 in the general French population using proportionality rules. Finally, we computed the expected number of infections that would have been expected in the French CF population had the risk of infection been the same as in the general population. We used the number of CF patients from the national registry as the denominator to compute the expected number of SARS-Cov-2 CF cases [1].
    [Show full text]
  • Clinical Guidance on COVID- 19 Vaccines for People with Cystic Fibrosis
    Clinical Guidance on COVID- 19 Vaccines for People with Cystic Fibrosis This guidance is intended for health-care providers. It is based on known evidence as of June 16, 2020. Background and Context The SARS-CoV-2 pandemic has been of particular concern for the cystic fibrosis (CF) community. CF is a multisystem condition with comorbidities that are expected to increase vulnerability to COVID-19. This guidance is based on a review of three of the vaccines approved by Health Canada for the prevention of COVID-19 disease caused by the SARS-CoV-2 virus: Pfizer-BioNTech (BNT162b2)1 and Moderna (mRNA-1273)2, both of which are mRNA vaccines, as well as AstraZeneca/COVISHIELD (ChADOx1-S)3 which is a replication defective adenoviral vector (‘viral vector’) vaccine. Currently, anyone aged 12+ (born in 2009 and later) in British Columbia is eligible for COVID-19 immunization. At this time, only the Pfizer-BioNTech mRNA vaccine is authorized for youth aged 12 and above,3 and we are expecting that Health Canada will authorize the Moderna mRNA vaccine for 12-17 year olds in the near future. Studies of the COVID-19 vaccines in younger children are ongoing. As per the National Advisory Committee on Immunization (NACI)4, the two mRNA vaccines authorized in Canada (Pfizer- BioNTech and Moderna) can be interchanged for the second dose to complete the series, if the vaccine received for the first dose is not available or is unknown. No data currently exist on the interchangeability of the COVID-19 mRNA vaccines. However, there is no reason to believe that mRNA vaccine series completion with a different authorized mRNA vaccine product will result in any additional safety issues of deficiency in protection.
    [Show full text]
  • COVID-19 & Cystic Fibrosis
    COVID-19 & Cystic Fibrosis People with cystic fibrosis (CF) may have anxiety about their health during the COVID-19 pandemic. However, there isn’t any evidence to suggest that those with CF are more likely to contract COVID-19 according to Dr. Jennifer Taylor-Cousar, co-director of the Adult Cystic Fibrosis Program at National Jewish Health. “What we do know is that those with CF are more at risk to have severe effects of COVID-19 on their lungs.” Cystic fibrosis patients are used to social distancing and taking extra precautions to keep from getting sick. In fact, these habits may be the reason that fewer than expected cystic fibrosis patients have reported contracting COVID-19. Dr. Taylor-Cousar says, “Overall, people with CF aren’t catching COVID-19 frequently, most likely because they are used to washing their hands frequently, staying home and staying six feet away from other people.” Routine Care for Cystic Fibrosis during COVID-19 The COVID-19 pandemic has made getting treatment for cystic fibrosis at health care centers harder. The Cystic Fibrosis Foundation recommends that patients see their doctors quarterly for an in depth checkup. During the pandemic, according to Dr. Taylor-Cousar, many health care providers are using telehealth to connect with CF patients. “Telehealth let’s doctors give patients advice about their medications, and anything that needs to change because of mild COVID symptoms without the patient having to leave their house,” she explained. COVID-19 Treatment for CF Patients If a cystic fibrosis patient does become sick with COVID-19, the patient’s treatment may look the same as a patient without CF.
    [Show full text]